Logan Reed
DNA vaccines have been a topic of interest since the 1990s, with research focusing on their potential advantages over traditional vaccines, such as their ability to induce a wider range of immune responses and their speed and ease of development. In 2021, India approved the world's first DNA vaccine for emergency human use, called ZyCoV-D, to combat COVID-19. This vaccine was developed by the Zydus Cadila pharmaceutical company and was found to be 67% effective in preventing serious illness from COVID-19. While this is a significant milestone, it is important to note that DNA vaccines have faced challenges in their development for human use, and their effectiveness is still being optimised.
| Characteristics | Values |
|---|---|
| Are there any DNA vaccines approved for humans? | Yes, ZyCoV-D, the world's first DNA vaccine for human use, was approved for emergency use in India in August/September 2021. |
| Date DNA vaccines were first proposed | Early 1990s |
| How DNA vaccines work | By injecting genetically engineered plasmids containing the DNA sequence encoding the antigen(s) against which an immune response is sought, causing a protective immunological response. |
| Advantages of DNA vaccines | Can be developed quickly, stable, compact, scalable, reasonably simple to administer, ability to induce a wider range of immune responses. |
| Disadvantages of DNA vaccines | Poorly immunogenic in humans, not associated with clinical benefit, concerns about potential genotoxicity risks. |
| Current research focus for DNA vaccines | To increase immunogenicity in humans, fight HIV and certain cancers, overcome inefficiencies of delivery to antigen-presenting cells. |
Explore related products
What You'll Learn
The first DNA vaccine for humans was approved in 2021
DNA vaccines were first proposed in the 1990s when it was discovered that intramuscular plasmid DNA injection could induce protein expression. In 1993, Jeffrey Ulmer and colleagues at Merck Research Laboratories demonstrated that direct injection of mice with plasmid DNA encoding a flu antigen protected the animals against subsequent experimental infection with the influenza virus. However, it wasn't until 2021 that the first DNA vaccine for human use was approved.
The Indian ZyCov-D vaccine, developed by Cadila Healthcare, was given emergency approval by Indian authorities in August 2021. It is the first DNA vaccine approved for humans and is designed to protect against SARS-CoV-2. The approval of this vaccine was accelerated by the worldwide need for a stable and scalable vaccine against SARS-CoV-2.
While DNA vaccines have been shown to be safe for humans, they have been poorly immunogenic. This means that they have not been associated with clinical benefits. However, the development of the ZyCov-D vaccine represents a significant milestone in the advancement of DNA vaccine technology.
DNA vaccines have several advantages over conventional vaccines. They are stable, compact, and reasonably simple to administer. They can also induce a wider range of immune responses. However, the discovery and development of optimal antigens remain a key challenge. Additionally, compared to conventional vaccines, DNA vaccines tend to have more severe side effects.
Despite these challenges, the approval of the first DNA vaccine for human use in 2021 marks a significant step forward in the field of vaccinology. It demonstrates the potential of DNA vaccines and opens up new possibilities for their use in the future.
The Varicella Vaccine: What's in a Name?
You may want to see also
Explore related products
DNA vaccines are stable, compact, and simple to administer
The concept of DNA vaccination was introduced in the early 1990s. Since then, advancements in the augmentation of the immunogenicity of DNA vaccines have brought this technology to the market, especially in veterinary medicine, to prevent many diseases. The Indian ZyCov-D vaccine, approved in 2021, is the first DNA vaccine for human use. It was designed to combat SARS-CoV-2.
DNA vaccines are stable, compact, and reasonably simple to administer. They are stable at room temperature, which is advantageous for transport and storage. This stability is due to DNA being an adjuvant when exposed in the cytosol. DNA vaccines are also compact and scalable. They are easy and inexpensive to make, and they produce strong, long-term immunity.
The discovery and development of optimal antigens are a key challenge in the creation of DNA vaccines. Scientific and engineering advances are being made regularly, and the fear of genome integration is seemingly over-weighted, as it is incredibly rare. The continued adherence to, and updating of, FDA regulations for monitoring adverse outcomes will lead to step-wise improvements in the safety of DNA vaccines.
The manufacturing process for DNA vaccines does not require a special delivery system. The vaccines are injected with a plasmid DNA encoding an antigen that protects against subsequent experimental infection. This process has been shown to be safe but remains poorly immunogenic, and the technique's usefulness remains to be proven in humans.
Hep A and B Vaccines: Dead Strains?
You may want to see also
Explore related products
DNA vaccines have been tested on humans for Zika and HIV
DNA vaccines were first introduced in the early 1990s when it was discovered that intramuscular plasmid DNA injection could induce protein expression. Since then, there have been rapid advancements in DNA vaccine technology, with improved plasmid engineering and the discovery of optimal antigens. While DNA vaccines have shown promise in veterinary medicine, their success in animals has not translated well to humans.
In 2016, a DNA vaccine for the Zika virus began human testing at the National Institutes of Health. Two DNA vaccines composed of the genes that encode the structural premembrane and envelope proteins of the Zika virus were tested in monkeys and showed promising results. This led to the initiation of phase 1 clinical trials to assess the safety, tolerability, and immunogenicity of the vaccines in healthy adults. The Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) developed two DNA vaccine candidates, VRC5288 and VRC5283, which were safe and immunogenic in non-human primate studies. These vaccines were then tested in regions with endemic Zika virus to further assess their efficacy.
In addition to Zika, DNA vaccines have also been tested on humans for HIV. Phase 1 clinical trials were conducted for a six-plasmid multiclade HIV-1 DNA candidate vaccine, with DNA vaccines being touted as a safe and efficient platform technology for responding to emerging infectious diseases.
While DNA vaccines have been tested on humans for Zika and HIV, as of 2021, only one DNA vaccine has been approved for emergency use in humans: the Indian ZyCoV-D vaccine against SARS-CoV-2. The approval of this vaccine was accelerated by the worldwide need for a stable and scalable vaccine. DNA vaccines hold potential for global vaccination campaigns due to their stability, compactness, scalability, and ease of administration. However, more research and advancements are needed to optimize DNA vaccines for human use fully.
Chickenpox Vaccine: Can Babies Still Spread the Virus?
You may want to see also
Explore related products
DNA vaccines are being studied to fight certain cancers
DNA vaccines have been studied for their potential to fight certain cancers. The concept of DNA vaccination was introduced in the early 1990s, and since then, advancements have been made to improve their immunogenicity and delivery methods. DNA vaccines work by injecting genetically engineered plasmids containing DNA sequences that encode specific antigens, stimulating an immune response. This technology has been effective in preventing and treating various diseases in veterinary medicine.
Therapeutic DNA cancer vaccines are considered a promising strategy to activate the immune system against cancer. Several clinical trials using plasmid DNA vaccines have demonstrated a good safety profile and the activation of a broad and specific immune response. However, these vaccines often show modest therapeutic effects due to the immunosuppressive nature of tumours. To enhance their efficacy, researchers are focusing on improving immunogenicity and combining DNA vaccines with complementary therapies.
The development of optimal antigens is a key challenge in DNA vaccine research. Scientists are exploring various approaches to increase immunogenicity and improve clinical outcomes, such as structural modifications and combination therapies with treatments like chemotherapy and radiotherapy. The use of AI tools has also been proposed to predict antigen immunogenicity and optimise DNA cancer vaccines.
While DNA vaccines for cancer show promise, they have yet to achieve significant success in humans compared to other genetic vaccine technologies. The first DNA vaccine for human use, the Indian ZyCovD vaccine against SARS-CoV-2, was approved in 2021. However, this vaccine is not specifically targeted at cancer. Researchers continue to investigate the potential of DNA vaccines in cancer treatment, with ongoing preclinical and clinical studies to address limitations and enhance their effectiveness.
Blood Clots and Vaccines: What's the Link?
You may want to see also
Explore related products
DNA vaccines have advantages over traditional vaccines
DNA vaccines have been applied to a wide range of infectious and malignant diseases. They are stable, compact, scalable, and reasonably simple to administer. They are also cheaper to make than traditional vaccines. Here are some advantages of DNA vaccines over traditional vaccines:
Ability to Induce a Wider Range of Immune Responses
DNA vaccines can induce a wider range of types of immune response compared to traditional vaccines. This is because they can be designed to express specific antigens or immunostimulatory molecules, allowing for a more targeted and diverse immune response.
Speed and Ease of Development
It is easier to create large amounts of genetic material (DNA) than to manufacture traditional vaccines, which often require growing bacteria or viruses. This speed and ease of development are crucial when responding to rapidly spreading and mutating diseases.
Safety
DNA vaccines are generally safe for humans and have been shown to be effective in preventing serious illness. For example, the ZyCoV-D DNA vaccine, which was approved for emergency use in India during the COVID-19 pandemic, was found to be 67% effective in preventing serious illness.
Effective Immunotherapy
DNA vaccines have been shown to be reliable forms of immunotherapy, making them promising candidates for treating cancers that are incurable by conventional therapies.
Simple Administration
DNA vaccines can be easily injected with needles and prepared in saline solutions. This simplicity makes them suitable for global vaccination campaigns.
While DNA vaccines have these advantages, it is important to note that they are not yet optimised for human use, and further research is needed to improve their immunogenicity in humans.
How Aminoglycosides Enhance Vaccine Efficacy
You may want to see also
Frequently asked questions
Yes, in August 2021, India approved the world's first DNA vaccine for emergency use in humans. The vaccine, called ZyCoV-D, was developed by the Zydus Cadila pharmaceutical company to fight COVID-19.
DNA vaccines work by injecting a genetically engineered plasmid containing the DNA sequence that encodes the antigen(s) against which an immune response is sought. This causes the cells to directly produce the antigen, thus triggering a protective immunological response.
DNA vaccines have several potential advantages over traditional and mRNA vaccines. They can be developed quickly as it is easier to create large amounts of a gene than to make proteins or grow bacteria or viruses. They are also highly stable and durable, and they do not change your existing genes or infect you with a disease.
